Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 13/20 | 0.60 |
| ▸ | LPL | P06858 | 12/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.39 |
| ▸ | F11 | P03951 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29888970 | 1.00 | LIPG (0.60) | LIPGLPLALDH1A1TSHRNOS1 | |
| Hydrochloric Acid SCHEMBL2006790 | 0.98 | LIPG (0.58) | LIPGLPLALDH1A1TSHRNOS1 | |
| SCHEMBL20768151 | 0.86 | LIPG (0.59) | LIPGLPLCHRNB2CHRNA4F11 | |
| SCHEMBL24364496 | 0.84 | LIPG (0.65) | LIPGLPLHTR7 | |
| SCHEMBL30470776 | 0.84 | LIPG (0.65) | LIPGLPLHTR7 | |
| SCHEMBL19421728 | 0.84 | LIPG (0.60) | LIPGLPLF11PYCR1 | |
| SCHEMBL3039403 | 0.83 | LIPG (0.63) | LIPGLPLF11 | |
| SCHEMBL4604189 | 0.83 | LIPG (0.52) | LIPGLPLALDH1A1 | |
| SCHEMBL30470578 | 0.82 | LIPG (0.70) | LIPGLPLNOS1HTR7 | |
| SCHEMBL24365983 | 0.82 | LIPG (0.70) | LIPGLPLNOS1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-12-26 | — | — | US | disclosed |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| EP-4330246-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | Ontario Institute for Cancer Research (OICR) (CA) | 2024-03-06 | — | — | EP | disclosed |
| CN-117597336-A | Halogen substituted amino aza-heteroaryl compounds as inhibitors of hematopoietic progenitor kinase 1 (HPK 1) | 安大略省癌症研究所(OICR) | 2024-02-23 | — | — | CN | disclosed |
| CN-116848113-A | Bicyclic compounds as HPK1 inhibitors and application thereof | 南京再明医药有限公司 | 2023-10-03 | — | — | CN | disclosed |
| EP-3152210-B1 | TANK-BINDING KINASE INHIBITOR COMPOUNDS | GILEAD SCIENCES INC (US) | 2023-07-05 | — | — | EP | disclosed |
| US-11492354-B2 | Indazole compounds and uses thereof | INCYTE CORPORATION (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3265453-B1 | NEW PYRIDINONES AND ISOQUINOLINONES AS INHIBITORS OF THE BROMODOMAIN BRD9 | BOEHRINGER INGELHEIM INT (DE) | 2022-06-29 | — | — | EP | disclosed |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-05-03 | — | — | US | disclosed |
| US-20210002288-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | INCYTE CORPORATION | 2021-01-07 | — | — | US | disclosed |
| US-7807686-B2 | 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists | N.V. ORGANON (NL) | 2010-10-05 | — | — | US | disclosed |
| US-7807686-B2 | 2-(4-oxo-4H-quinazolin-3-yl)acetamides and their use as vasopressin V3 antagonists | N.V. ORGANON (NL) | 2010-10-05 | — | — | US | disclosed |
| EP-1861380-B1 | 2-(4-OXO-4H-QUINAZOLIN-3-YL)ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | ORGANON NV (NL) | 2010-07-07 | — | — | EP | disclosed |
| EP-1861380-B1 | 2-(4-OXO-4H-QUINAZOLIN-3-YL)ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | ORGANON NV (NL) | 2010-07-07 | — | — | EP | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | MERCK SHARP & DOHME B.V. (NL) | 2008-09-04 | — | — | US | disclosed |
| EP-1861380-A1 | 2-(4-OXO-4H-QUINAZOLIN-3-YL)ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | N.V. Organon (NL) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006095014-A1 | 2- (4-0X0-4H-QUINAZ0LIN-3-YL) ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | N.V. ORGANON (NL) | 2006-09-14 | — | — | WO | disclosed |
| WO-2006095014-A1 | 2- (4-0X0-4H-QUINAZ0LIN-3-YL) ACETAMIDES AND THEIR USE AS VASOPRESSIN V3 ANTAGONISTS | N.V. ORGANON (NL) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214553-A1 | 2-(4-Oxo-4H-Quinazolin-3-Yl) Acetamides and Their Use as Vasopressin V3 Antagonists | AVPR2, AVPR1A, AVPR1B | LIPG 3810/4885LPL 4742/4885ALDH1A1 1928/4885 |
| US-20210002288-A1 | INDAZOLE COMPOUNDS AND USES THEREOF | PDXK, PPIP5K2, PCK1 | LIPG 2079/4885LPL 1586/4885ALDH1A1 2472/4885 |
| US-11319318-B2 | Pyridinones and isoquinolinones as inhibitors of the bromodomain BRD9 | BRD9, BRD1, BRD2 | LIPG 4757/4885LPL 4427/4885ALDH1A1 2461/4885 |
| US-11492354-B2 | Indazole compounds and uses thereof | PDXK, PPIP5K2, PCK1 | LIPG 2079/4885LPL 1586/4885ALDH1A1 2472/4885 |
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | LIPG 3807/4885LPL 3952/4885ALDH1A1 1521/4885 |
| US-20240425479-A1 | HALO-SUBSTITUTED AMINO AZA-HETEROARYL COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | DCK, CMPK1, WNK1 | LIPG 2562/4885LPL 2634/4885ALDH1A1 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.